The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Open accessAbstract
BACKGROUND: Calcific aortic stenosis has many characteristics in common with atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression. METHODS: In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were randomly assigned to receive either 80 mg of atorvastatin daily or a matched placebo. Aortic-valve stenosis and calcification were assessed with the use of Doppler echocardiography and helical computed tomography, respectively. The primary end points were change in aortic-jet velocity and aortic-valve calcium score. RESULTS: Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol concentrations remained at 130+/-30 mg per deciliter in the placebo group and fell to 63+/-23 mg per deciliter in the atorvastatin group (P<0.001). Increases in aortic-jet velocity were 0.199+/-0.210 m per second per year in the atorvastatin group and 0.203+/-0.208 m per second per year in the placebo group (P=0.95; adjusted mean difference, 0.002; 95 percent confidence interval, -0.066 to 0.070 m per second per year). Progression in valvular calcification was 22.3+/-21.0 percent per year in the atorvastatin group, and 21.7+/-19.8 percent per year in the placebo group (P=0.93; ratio of post-treatment aortic-valve calcium score, 0.998; 95 percent confidence interval, 0.947 to 1.050). CONCLUSIONS: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression. This study cannot exclude a small reduction in the rate of disease progression or a significant reduction in major clinical end points. Long-term, large-scale, randomized, controlled trials are needed to establish the role of statin therapy in patients with calcific aortic stenosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“several randomized trials showed no effect of statins on haemodynamic progression or AS-related clinical events152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three randomized clinical trials (RCTs) failed to demonstrate any significant benefit of LDL lowering with statins on the progression of AS152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“Several intervention studies have been performed to test the hypothesis that lipid lowering with statin medications would slow the progression of AS, however the results were generally disappointing152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“randomized controlled trials (RCTs) failed to demonstrate any benefit of statin therapy on retard disease progression6–8.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Several clinical trials evaluating statin therapy in mild to moderate AS failed to demonstrate efficacy in lipid lowering as a strategy to mitigate adverse events in the disease39–41.”
From Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction (2026) · cites this paper as [39]
In the citing paper
“lipid-lowering therapy to delay progression of AS has been evaluated in 3 randomized controlled trials; however, all trials reported no significant benefit.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“The SALTIRE (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression) and ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trials, which evaluated statin efficacy in AS, were constrained by small sample sizes (n=150 and n=269), 12,13 limited median follow-up periods (25 and 42 months), and a focus on advanced AS stages (mean peak velocity, 3.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“All of the clinical trials aimed to halt the progression of established AS.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Second, we observed similar associations with AVR as a strict procedural outcome, which is particularly meaningful in the context of previous neutral clinical trials of lipid-lowering therapies that used AVR as the study end point.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12% per mmol/L reduction in LDL cholesterol), MI, and vascular death [459,460].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [459]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Suggestions for an association between aortic stenosis, LDL-C and Lp(a), as well as between cholesterol and increased risk for calcification of bioprosthetic valves, were matched with early observational noncontrolled trials that showed beneficial effects of aggressive lipid lowering in slowing the progression of aortic stenosis. However, this was not confirmed in RCTs. 243,377,378”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Zoghbi, W. A., Enriquez-Sarano, M. L., Foster, E., Grayburn, P. A., Kraft, C. D., Levine, R. A., Nihoyannopoulos, P., Otto, C. M., Quiñones, M. A., Rakowski, H., et al. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00335-3 · Cited by 4,041
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis
Rosenhek, R., Binder, T. M., Porenta, G., Lang, I. M., Christ, G., SCHEMPER, M., Maurer, G., & Baumgartner, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430903 · Cited by 1,332
Otto, C. M., Kuusisto, J., Reichenbach, D. D., Gown, A. M., & O’Brien, K. D. (1994) · Circulation · doi:10.1161/01.cir.90.2.844 · Cited by 1,315
Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly
Otto, C. M., Lind, B. K., Kitzman, D. W., Gersh, B. J., & Siscovick, D. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410302 · Cited by 1,281
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Moghadam, R. H., Babajani, F., Karami, A., Komi, D. E. A., Hoseini, F., Salehi, N., elahirad, S., Noori, E. M., Mohammadi, H., & Kiani, A. (2024) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2023.0370 · Cited by 1
Unraveling the Enigma of Moderate Aortic Stenosis: Challenges and Future Prospects
Santangelo, G., Tumminello, G., Barbieri, L., Mallardi, G. P. F., Faggiano, A., Moscardelli, S., Rossi, A., Cozza, F., Carugo, S., & Faggiano, P. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123478 · Cited by 1
Dayan, V., Montero, J. A., & Freemantle, N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312408 · Cited by 1
Клинико-генетические предикторы развития кальцинированного аортального стеноза
К.В., П., Дадабаев, Г. М., И.В., С., & Chobanyan, M. A. (2024) · Kreativnaya kardiologiya · doi:10.24022/1997-3187-2024-18-3-309-316 · Cited by 1
Xiang, H., Zhang, Y., Zhang, Y., Ye, Z., Yang, S., Gan, X., Huang, Y., Wu, Y., Zhang, Y., & Qin, X. (2025) · Heart · doi:10.1136/heartjnl-2025-326161 · Cited by 1
Mei, Z., Guo, C., Yang, H., Li, J., Chang, M., Zhang, C., Ni, M., Chen, L., Gao, W. D., Liu, X., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133706 · Cited by 1
Rosenhek, R., & Baumgartner, H. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4860-0.00011-6 · Cited by 1
Geriatric Aspects of Aortic Stenosis
Tufan, F., Öz, F., Omer, A., & Oflaz, H. (2011) · InTech eBooks · doi:10.5772/22190 · Cited by 1
Valvular Heart Disease in Heart Failure
Mookadam, F., Moustafa, S., & Malouf, J. F. (2010) · Springer eBooks · doi:10.1007/978-1-84996-153-0_3 · Cited by 1
Sagie, A., & Dvir, D. (2009) · F1000 Medicine Reports · doi:10.3410/m1-26 · Cited by 1
Valvular Heart Disease in the Elderly
Cawley, P. J., & Otto, C. M. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0187-z · Cited by 1
Rajamannan, N. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-411-7_2 · Cited by 1
MECHANISMS OF ANGIOGENESISAND LYMPHANGIOGENESIS
Syväranta, S. (2013) · Cited by 1
Gillis, K., Roosens, B., Bala, G., Remory, I., Hernot, S., Delvenne, P., Mestrez, F., Droogmans, S., & Cosyns, B. (2017) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2017.1311138 · Cited by 1
Valvular Heart Disease in Critical Care
Turi, Z. G. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50035-2 · Cited by 1
Sreedharan, A. V., Pek, S. L. T., Tan, T. H., Subramaniam, T., & Yap, F. K. P. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.07.006 · Cited by 1
Aortic and Pulmonic Valvular Heart Disease
Crousillat, D. R., Klassen, S. L., Elmariah, S., Passeri, J. J., & Palacios, I. F. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_20 · Cited by 1
Jin, Y., Wang, Y., Weng, Y., Li, X., Huang, Q., Liu, Y., Xiang, Y., Li, X., Jiang, P., He, W., et al. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105002 · Cited by 1
Sebastian, J. L., & Pfeifer, K. J. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2261-9.50034-3 · Cited by 1
Chen, J., Sun, Y., Xiong, T., Wang, G.-N., & Chang, Q. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9558713 · Cited by 1
RetractedKumar, P., Aedma, S. K., Varadarajan, P., & Pai, R. G. (2022) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2022.10.021 · Cited by 1
Xiong, T., Chen, Y., Shen, H., Zhang, T.-C., Pu, L., Fan, Y., Fan, W.-C., Zhang, Y.-Y., & Li, Y.-X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.913776 · Cited by 1
Aortic stenosis progression: Still a long way to go
Prosperi‐Porta, G., Willner, N. A., & Messika–Zeitoun, D. (2023) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2023.01.002 · Cited by 1
Feng, D., Ye, Y., Li, Z., Zhang, B., Liu, Q., Wang, W., Zhao, Z., Zhou, Z., Zhao, Q., Yu, Z., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.08.049 · Cited by 1
Sokolskaya, M. A., Шварц, В. А., Петросян, А. Д., Мироненко, М. Ю., Жарикова, А. Е., & Бокерия, Л. А. (2023) · The Bulletin of Bakoulev Center Cardiovascular Diseases · doi:10.24022/1810-0694-2023-24-6-598-606 · Cited by 1
Redefining the natural history of calcific aortic stenosis: lessons from Laennec
Sverdlov, A. L., Ngo, D. T. M., & Horowitz, J. D. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02520.x · Cited by 1
Aortic stenosis: From diagnosis to optimal treatment
Tavčiovski, D., & Davicevic, Z. (2008) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh0804176t · Cited by 1
Timing of surgery in aortic stenosis
Mohan, S. B., & Stouffer, G. A. (2006) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-006-0029-3 · Cited by 1
Statins and aortic stenosis progression: Are biologic targets still an option?
Pai, R. G. (2005) · Current Cardiology Reports · doi:10.1007/s11886-005-0055-x · Cited by 1
Relationship between High-Density Lipoprotein and the Progression of Aortic Valvular Disease
Yontar, O. C., & Yılmaz, M. B. (2009) · Journal of Cardiac Surgery · doi:10.1111/j.1540-8191.2009.00893.x · Cited by 1
Importance of serum high‐density lipoprotein levels to aortic valvular disease
Yontar, O. C., & Yılmaz, M. B. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.348 · Cited by 1
Degenerative calcific aortic valve disease: from pathogenic to epidemiological characterization
Sanchez, P. L., de la Pompa, J. L., Román, J. A. S., Arroyo, A. G., Martín‐Luengo, C., Pinar, J., González, I. F., Martínez‐Sellés, M., & Tornos, P. (2008) · ABACUS. Repositorio de Producción Científica (Universidad Europea) · Cited by 1
Update in the Clinical Management of Valvular Heart Disease
Akhter, M. W., & Rahimtoola, S. H. (2007) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(07)60164-9 · Cited by 1
Independent predictors of postoperative atrial fibrillation
Ramaraj, R. (2009) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.08.009 · Cited by 1
Raggi, P. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.04.006 · Cited by 1
Aortic Stenosis: It Is a Hot Topic
Carabello, B. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.035 · Cited by 1
Valvular heart disease: the unanswered questions
Prendergast, B., Fajadet, J. C., Tamburino, C., Haude, M., & Windecker, S. (2015) · EuroIntervention · doi:10.4244/eijv11swa2 · Cited by 1
The dynamic interaction of coronary circulation, left ventricle and aortic valve during exercise
Lumley, M. (2016) · Research Portal (King's College London) · Cited by 1
Goswami, R., Tran, P., Hieu, N. L., Nanjundappa, A., & Kleiman, N. S. (2016) · Wiley eBooks · doi:10.1002/9781118965061.ch11 · Cited by 1
Aronow, W. S. (2007) · Comprehensive Therapy · doi:10.1007/s12019-007-8021-8 · Cited by 1
Synopsis of Adult Cardiac Surgical Disease
Bojar, R. M. (2010) · Wiley eBooks · doi:10.1002/9781444325287.ch1 · Cited by 1
Tavenier, A. H., Nicolas, J., & Mehran, R. (2022) · US Cardiology Review · doi:10.15420/usc.2022.07 · Cited by 1
Sarin, E. L., & Thourani, V. H. (2019) · IGI Global eBooks · doi:10.4018/978-1-5225-8185-7.ch019 · Cited by 1
Rossebø, A. B., Gerdts, E., & Pedersen, T. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61104-1 · Cited by 1
oxLDL-induced aortic valve inflammation and calcification: opportunities for clinical translation
Wang, Y.-J., Matter, M. A., & Matter, C. M. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf166 · Cited by 1
Aortic and mitral valve disease: surgical implications of oxidative stress
Kassem, S. (2012) · DSpaceUnipr (University of Parma)
Medical Therapy of Valvular Heart Disease
Parikh, S. A., & O’Gara, P. T. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-411-7_16
Hartziekten Bij Oudere Vrouwen
Bakx, C., & Maas, A. H. E. M. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8782-3_7
Die Aortenklappenstenose beim Erwachsenen. Teil 1. Ätiologie, Pathophysiologie und Diagnose
Christen, T., Lerch, R., & Trindade, P. T. (2006) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2006.05906
Hoefen, R. J., & Storozynsky, E. (2009) · Springer eBooks · doi:10.1007/978-1-84882-185-9_6
Current Treatment Options in Aortic Stenosis
Öz, F., Tufan, F., Ekmekçi, A., Omer, A., & Oflaz, H. (2013) · InTech eBooks · doi:10.5772/54355
Aortic Stenosis - New Insights in Stenosis Progression and in Prevention
Alessandro, P., Trezzi, M., Merati, E., Filippini, S., & Alamanni, F. (2011) · InTech eBooks · doi:10.5772/23838
Bicuspid Aortic Valve without Stenosis
Hoffman, J. I. E. (2009) · Wiley eBooks · doi:10.1002/9781444314045.ch25
Proteomics - A Powerful Tool to Deepen the Molecular Mechanisms of Aortic Stenosis Disease
Gil-Dones, F., de la Cuesta, F., Álvarez‐Llamas, G., Luis, R., Luis, F., Martín-Rojas, T., Vivanco, F., & María, G. S. D. S. (2011) · InTech eBooks · doi:10.5772/20611
The Progression of Aortic Sclerosis to Aortic Stenosis
Jalal, U., & Mookadam, F. (2011) · InTech eBooks · doi:10.5772/21562
WINCHESTER, R. J., & Kodali, S. (2011) · InTech eBooks · doi:10.5772/19209
Transapical valve technology for aortic stenosis
Grünenfelder, J., Kofidis, T., Plass, A., & Falk, V. (2013) · Wiley eBooks · doi:10.1002/9781118504536.ch15
Breast Arterial Calcifications and Heart Disease Risk in women
Maas, A. H. E. M. (2006) · Utrecht University Repository (Utrecht University)
Überraschende Ergebnisse der SEAS-Studie
Graf, K. (2008) · Der Kardiologe · doi:10.1007/s12181-008-0117-6
Vascular calcifications and matrix Gla protein in hypertensive subjects
Rennenberg, R. J. M. W. (2011) · doi:10.26481/dis.20110706rr
Native and Prosthetic Valve Stenosis
Huang, P., & Faxon, D. P. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2798-7_9
Dezellularisierte Aorten-Conduits und ihre Biokompatibilität
Assmann, A., Akhyari, P., & Lichtenberg, A. (2014) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-014-1108-5
Surgical Indications in Aortic Valve Disease
Mankad, S. V., Connolly, H. M., & Rahimtoola, S. H. (2009) · Wiley eBooks · doi:10.1002/9781444309768.ch55
Asymptomatic Aortic Stenosis - Prognosis, Risk Stratification and Follow-Up
Paoli, U., & Dichtl, W. (2011) · InTech eBooks · doi:10.5772/22068
Thorakale und abdominale Aorta
Luska, G. (2007) · Springer eBooks · doi:10.1007/978-3-540-69018-4_7
39 Aorta- en mitralisklepafwijkingen
Hamer, J. P. M. (2008) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-7029-0_39
Statins in the Reduction of Cardiovascular Events
Sachdeva, R., Hughes, B. R., & Mehta, J. L. (2011) · Wiley eBooks · doi:10.1002/9780470571224.pse450
Application of the LDL-Density-Radius Theory: The Aortic Valve
Rajamannan, N. M., Antonini‐Canterin, F., & Wachtal, K. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6350-3_17
Identification of Early Pathological Events in Calcific Aortic Valve Disease by Molecular Imaging
Martínez‐Martínez, E., & Aïkawa, E. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6350-3_13
Estatinas en la estenosis aórtica
Tavella, N. (2007) · Redalyc (Universidad Autónoma del Estado de México)
Potential Role of Statin Therapy in Heart Failure, Atrial Fibrillation and Aortic Stenosis
Nagamia, S. H., Thoenes, M., Khan, Q. A., Pandian, A., & Khan, B. V. (2006) · Future Cardiology · doi:10.2217/14796678.2.6.687
Semb, A. G., Provan, S. A., Kvien, T. K., & Pedersen, T. (2009) · BMJ Case Reports · doi:10.1136/bcr.08.2008.0717
Is Aortic Bioprosthesis Degeneration Influenced by Metabolic Factors?
Rossebø, A. B. (2012) · Cardiology · doi:10.1159/000338565
Chondromodulin-I maintains normal cardiac valves by preventing angiogensis
Hakuno, D., Kimura, N., Yoshioka, M., & Fukuda, K. (2007) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2007.09.007
La reducción del colesterol con rosuvastatina no frena la progresión de la estenosis aórtica
Robredo, B. G., Marroquín, E. C., & Velázquez, C. B. (2011) · Farmacéuticos de Atención Primaria · doi:10.1016/s2172-3761(11)70021-8
The doubtful association between blood lipid changes and progression of coronary calcification
Tenenbaum, A., Fisman, E. Z., Shemesh, J., & Motro, M. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.058
Adiponectin: A Novel Target for Aortic Stenosis Medical Treatment?
Zamorano, J. L., & Gonçalves, A. (2011) · Cardiology · doi:10.1159/000329827
Actualización en valvulopatías (I)
García, M. V., García, M. D. E., & Sánchez, M. C. C. (2008) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(08)70847-8
Messika–Zeitoun, D. (2013) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(13)65328-3
Patient Selection, Statistical Presumption, and Uncertainty of Outcomes
Scheidt, S. S., WENGER, N. K., & Weber, M. A. (2007) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2007.06226.x
Statins therapy for calcific aortic valve disease: Yes, but not all
Fang, M., Wang, T., Li, J., & Li, X. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.01.035
An elderly man who suddenly lost consciousness
Ramaraj, R. (2009) · BMJ · doi:10.1136/bmj.a3009
Borràs, X., Barrios, V., Escobar, C., & Pedreira, M. (2007) · Revista Española de Cardiología · doi:10.1157/13099717
Kamalesh, M., Ng, C., & Eckert, G. J. (2009) · Clinical Cardiology · doi:10.1002/clc.20541
Retractedvan Geldorp, M. W. A., & Takkenberg, J. J. M. (2009) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.08.030
Congenital Aortic Stenosis and Aneurysms
van der Linde, D. (2013)
Vánky, F. B. (2006) · DiVA (Linkoping University)
Estenosis aórtica en el anciano
Martínez‐Sellés, M. (2011) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(11)70216-x
Recent advances in valvular heart disease
Rayner, J., & Prendergast, B. (2013) · F1000Prime Reports · doi:10.12703/p5-31
"VALVULO-METABOLIC" RISK IN AORTIC STENOSIS
Pîbarot, P. (2008)
Lipoprotein levels and the progression of aortic valvular disease.
Yontar, O. C., & Yılmaz, M. B. (2009) · PubMed
Aortic stenosis part two: Diagnostic testing, evaluation and management
Potts, K., & Hill, S. J. (2007) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2007.2.7.23805
Associations between cardiovascular risk factors, hyper- and hypocoagulability
Rafi, S. (2011) · UvA-DARE (University of Amsterdam)
Hunting to Prevent Aortic Stenosis
Hoit, B. D. (2010) · Circulation · doi:10.1161/cir.0b013e3181d41019
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Yip, C. Y. Y. (2010) · TSpace (University of Toronto)
Metadata
- Authors
- Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A.
- Affiliations
- Edinburgh Royal Infirmary (GB)
- University of Edinburgh (GB)
- Borders General Hospital (GB)
- Western General Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-09
- Volume
- 352
- Issue
- 23
- Pages
- 2389-2397
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2117330772
- Cited by
- 1,146
- References
- 41
- Citations by year
- 2026: 46 · 2025: 52 · 2024: 57 · 2023: 37 · 2022: 47 · 2021: 44 · 2020: 59 · 2019: 38 · 2018: 39 · 2017: 52 · 2016: 52 · 2015: 37 · 2014: 65 · 2013: 64 · 2012: 55
- FWCI
- 47.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- calcific aortic stenosis, atorvastatin, statin therapy, lipid-lowering therapy, valve calcification, disease progression, aortic jet velocity, aortic valve calcium score, LDL cholesterol, hypercholesterolemia, atherosclerosis, echocardiography, CT angiography
- MeSH terms
- Atorvastatin, Anticholesteremic Agents, Aortic Valve, Aortic Valve Stenosis, Blood Flow Velocity, Calcinosis, Double-Blind Method, Heptanoic Acids, Humans, Cholesterol, LDL, Pyrroles, Echocardiography, Doppler, Treatment Failure, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
